NCT00560963已完成1 期
Combination of Antiangiogenic Therapy Using the mTOR-inhibitor RAD001 and Low Dose Chemotherapy for Locally Advanced and/or Metastatic Pancreatic Cancer - a Dose Finding Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of everolimus in combination with Gemcitabine
研究概览
简要总结
A dose finding study in locally advanced and/or metastatic pancreatic cancer patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1 RAD001
Experimental
干预措施: everolimus (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of everolimus in combination with Gemcitabine
时间窗: 8 weeks
次要结局
- Safety & tolerability, pharmacokinetic assessments of Everolimus and Gemcitabine combination therapy in these patient populations. Phase II objective response rates (ORR), duration of response, progression-free survival (PFS), overall survival (OS)(36 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)Carcinoma, Pancreatic DuctalNCT01808638Silence Therapeutics GmbH29
已完成
1 期
BATs Treatment for Pancreatic Cancer, Phase Ib/IILocally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaNCT03269526University of Virginia22
尚未招募
不适用
Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided RadiotherapyLocally Advanced Pancreatic AdenocarcinomaNCT06272162UMC Utrecht150
终止
1 期
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care TherapyPancreatic CancerNCT03136406ImmunityBio, Inc.3
已完成
3 期
Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic CancerPancreatic CancerNCT00498225Taiho Pharmaceutical Co., Ltd.834